|
1
|
Lynch HT, Snyder CL, Shaw TG, Heinen CD
and Hitchins MP: Milestones of Lynch syndrome: 1895–2015. Nat Rev
Cancer. 15:181–194. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcus L, Lemery SJ, Keegan P and Pazdur
R: FDA approval summary: Pembrolizumab for the treatment of
microsatellite instability-high solid tumors. Clin Cancer Res.
25:3753–3758. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Food and Drug Administration (FDA), . FDA
grants accelerated approval to pembrolizumab for first tissue/site
agnostic indicationFDA; Silver Spring, MD: 2018, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htmJuly.
30, 2018
|
|
5
|
Win AK, Parry S, Parry B, Kalady MF,
Macrae FA, Ahnen DJ, Young GP, Lipton L, Winship I, Boussioutas A,
et al: Risk of metachronous colon cancer following surgery for
rectal cancer in mismatch repair gene mutation carriers. Ann Surg
Oncol. 20:1829–1836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Obermair A, Youlden DR, Young JP, Lindor
NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R, Jenkins MA,
et al: Risk of endometrial cancer for women diagnosed with
HNPCC-related colorectal carcinoma. Int J Cancer. 127:2678–2684.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eble JL, Sauter G and Epstein JI:
Pathology and genetics of tumours of the urinary system and male
genital organs: WHO classification of tumours. World Health Organ.
2004.
|
|
8
|
Bianchi F, Rosati S, Belvederesi L,
Loretelli C, Catalani R, Mandolesi A, Bracci R, Bearzi I, Porfiri E
and Cellerino R: MSH2 splice site mutation and endometrial cancer.
Int J Gynecol Cancer. 16:1419–1423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rakobradović J, Krivokuća A, Jovandić S,
Kesić V and Branković-Magić M: Confirmation of damaging effect of
MSH2 c. 2634+ 1G>C mutation on splicing, its classification and
implications for counseling. Cancer Genet. 239:1–7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for Molecular
Pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Q, Wang LA, Su J, Tong D, Lan W, Wang
L, Liu G, Zhang J, Zhang VW, Zhang D, et al: Giant bilateral
adrenal myelolipomas in two Chinese families with congenital
adrenal hyperplasia. Endocr Connect. Sep 1–2018.(Epub ahead of
print). View Article : Google Scholar
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bonadona V, Bonaiti B, Olschwang S,
Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ,
Caron O, et al: Cancer risks associated with germline mutations in
MLH1, MSH2 and MSH6 genes in Lynch syndrome. JAMA. 305:2304–2310.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Møller P, Seppälä T, Bernstein I,
Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I,
Sijmons R, et al: Cancer incidence and survival in Lynch syndrome
patients receiving colonoscopic and gynaecological surveillance:
First report from the prospective Lynch syndrome database. Gut.
66:464–472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Møller P, Seppälä TT, Bernstein I,
Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F,
Blanco I, Sijmons RH, et al: Cancer risk and survival in path_MMR
carriers by gene and gender up to 75 years of age: A report from
the Prospective Lynch Syndrome Database. Gut. 67:1306–1316. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casper M, Weber SN, Kloor M, Müllenbach R,
Grobholz R, Lammert F and Zimmer V: Hepatocellular carcinoma as
extracolonic manifestation of Lynch syndrome indicates SEC63 as
potential target gene in hepatocarcinogenesis. Scand J
Gastroenterol. 48:344–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vernez M, Hutter P, Monnerat C, Halkic N,
Gugerli O and Bouzourene H: A case of Muir-Torre syndrome
associated with mucinous hepatic cholangiocarcinoma and a novel
germline mutation of the MSH2 gene. Fam Cancer. 6:141–145. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan H, Jin H, Xue G, Mei Q, Ding F, Hao L
and Sun SH: Germline hMSH2 promoter mutation in a Chinese HNPCC
kindred: Evidence for dual role of LOH. Clin Genet. 72:556–561.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hemminki A, Peltomäki P, Mecklin JP,
Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A and
Aaltonen LA: Loss of the wild type MLH1 gene is a feature of
hereditary nonpolyposis colorectal cancer. Nat Genet. 8:405–410.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Gao J and Wu X: Pseudoprogression
and hyperprogression after checkpoint blockade. Int
Immunopharmacol. 58:125–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agarwala SS: Practical approaches to
immunotherapy in the clinic. Semin Oncol. 42 (Suppl 3):S20–S27.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guibert N, Mazieres J, Delaunay M,
Casanova A, Farella M, Keller L, Favre G and Pradines A: Monitoring
of KRAS-mutated ctDNA to discriminate pseudo-progression from true
progression during anti-PD-1 treatment of lung adenocarcinoma.
Oncotarget. 8:38056–38060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JH, Long GV, Menzies AM, Lo S,
Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H
and Carlino MS: Association between circulating tumor DNA and
pseudoprogression in patients with metastatic melanoma treated with
anti-programmed cell death 1 antibodies. JAMA Oncol. 4:717–721.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced Urothelial
Carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vanderwalde A, Spetzler D, Xiao N,
Gatalica Z and Marshall J: Microsatellite instability status
determined by next-generation sequencing and compared with PD-L1
and tumor mutational burden in 11,348 patients. Cancer Med.
7:746–756. 2018. View Article : Google Scholar : PubMed/NCBI
|
